[1] 范娜,任雅丽.降压药处方用药情况分析[J].临床合理用药,2017,10(5):1-2.
[2] 张斌.抗高血压药物门诊处方抽查结果分析[J]. 中国卫生标准管理. 2019,10(22): 88-90.
[3] 王淑霞.处方点评对于合理应用高血压药物的促进作用分析[J]. 中国现代药物应用. 2020,14(6):192-194.
[4] 王丽君,李亚东,高绪霞,等.医院门诊抗高血压药物应用现况研究[J],中国医药,2018,13(3):354-358.
[5] 方宁远.血管紧张素受体拮抗剂与利尿剂在单纯收缩期高血压治疗中的协同效应[J].中华高血压杂志,2017,25(11),1027-1030. [6] 中国医师协会全科医师分会.贝那普利氢氯噻嗪片基层临床应用全科专家共识[J].中国全科医学,2021,24(11),1309-1324.
[7] 王鸿懿,吴芳,王及华,等.阿利沙坦酯联合利尿剂或钙通道阻滞剂对单药治疗未达标高血压患者的疗效及安全性[J].中华高血压杂志,2021,29(5),420-427.
[8] Suchard MA, Schuemie MJ, Krumholz HM, et al.Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis[J].Lancet, 2019, 394(10211):1816-1826.
[9] 傅宴,郑国燕,陈春晖,等.一线高血压治疗药物对临床不良事件发生影响荟萃分析[J].中华高血压杂志,2021,29(7):676-681.
[10] Guideline for the pharmacological treatment of hypertension in adults [Internet]. Geneva,Guideline for the pharmacological treatment of hypertension in adults [Internet]. Geneva, World Health Organization, 2021.
[11] Rabi DM, McBrien KA, Sapir-Pichhadze R,et al.Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children[J].Can J Cardiol, 2020, 36(5):596-624.
[12] 2019 中国老年医学学会高血压分会,国家老年疾病临床医学研究中心中国老年心血管病防治联盟.中国老年高血压管理指南[J].中华老年多器官疾病杂志,2019, 18,(2),81-106.
[13] International Society of Hypertension.2020 International Society of Hypertension global hypertension practice guidelines[J].J Hypertens, 2020, 38(6):982-1004.
[14] 国家卫生计生委合理用药专家委员会,中国医师协会高血压专业委员会.高血压合理用药指南(第 2 版)[J].中国医学前沿杂志(电子版),2017,9(7),28-126.
[15] Hiremath S, Sapir-Pichhadze R, Nakhla M, et al.Hypertension Canada's 2020 Evidence Review and Guidelines for the Management of Resistant Hypertension[J].Can J Cardiol, 2020, 36(5):625-634.
[16] 吴海英, 新版美国高血压指南对我国高血压管理的启示[J].中华高血压杂志,2018,26(12):1108-1110.
[17] Marcum Z, Cohen JB,Zhang C, et al.Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment[J].JAMA Netw Open, 2022, 5(1):e2145319.
[18] 王云,刘希波,曹静,等,药物治疗盐敏感性高血压效果的系统评价和荟萃分析[J].中华医学杂志,2019, 99(30);2367-2374.
[19] Rik H Golde Engberink, Wijnanda J Frenkel, Bas van den Bogaard, et al.Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis[J].Hypertension,2015, 65(5):1033-1040.
[20] George C Roush, Michael E Ernst, John B Kostis, et al.Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects[J].Hypertension, 2015, 65(5):1041-1046
[21] 李强,沈丽霞,李明春,等.抗高血压药物噻嗪类利尿剂应用新进展[J].中国药业, 2021,30(19):1-4.
[22] Anil Pareek, Franz H Messerli, Gustavo Saraviaet al.Interamerican Society of Cardiology (IASC) position statement:Chlorthalidone vs. thiazide-type diuretics[J].Int J Cardiol Hypertens, 2020, 7:100054.
[23] Rajiv Agarwal, Arjun D Sinha, Andrew E Cramer, et al.Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease[J].N Engl J Med, 2021, 385(27):2507-2519.
[24] Zachary A Marcum, Jordana B Cohen,?Chong Zhang, et al.Association of Antihypertensives That Stimulate vs Inhibit Types 2 and 4 Angiotensin II Receptors With Cognitive Impairment[J].2022, 5(1):e2145319.
[25] 邢开,龚金玉,罗建权.噻嗪类利尿剂相关不良反应的药物基因组学研究进展[J],中国临床药理学与治疗学,2021;26(2),204-212.
[26] Martins VM, Ziegelmann PK, Helal L, et al.Thiazide diuretics alone or in combination with a potassium-sparing diuretic on blood pressure-lowering in patients with primary hypertension: protocol for a systematic review and network meta-analysis[J].Syst Rev, 2022, 11(1):23.
[27] Michael E Ernst, Michelle A Fravel.Thiazide and the Thiazide-Like Diuretics: Review of Hydrochlorothiazide, Chlorthalidone, and Indapamide[J].Am J Hypertens, 2022, 35(7):573-586. |
